Telepatia Raises $33M Series A for AI Healthtech Expansion

Telepatia, an innovative healthtech firm leveraging artificial intelligence to streamline clinical operations, has successfully closed a $33 million Series A funding round. The significant investment was spearheaded by prominent venture capital firm Andreessen Horowitz (a16z), signaling strong confidence in Telepatia's disruptive potential within the global healthcare sector.

The fresh capital infusion will fuel Telepatia's ambitious expansion plans, targeting not only broader adoption across Latin America but also strategic entry into underserved healthcare markets in India, Africa, and Southeast Asia. This global outlook underscores the company's vision to address critical healthcare access and efficiency challenges worldwide.

Founded in 2025 by CEO Nicolas Abad, Telepatia has rapidly established a robust operational footprint. The company's AI-driven platform integrates advanced capabilities such as real-time consultation transcription, intelligent medical record review, proactive identification of potential drug interactions, and AI-powered clinical decision support. These tools are designed to augment the capacity of healthcare professionals, enhancing diagnostic accuracy and operational efficiency.

Telepatia's technology has already demonstrated substantial impact, having supported over 14 million patient encounters across more than 25 public and private healthcare institutions. Its current reach spans key Latin American markets including Brazil, Colombia, Mexico, Chile, and Argentina, showcasing its ability to scale and adapt to diverse healthcare systems.

This Series A round saw participation from other notable investors, including Shyam Sankar, Simón Borrero, and David Vélez, further validating Telepatia's technological advancements and market traction. The company's unique approach, combining AI assistants with clinical decision support, positions it at the forefront of a healthtech revolution aimed at improving patient outcomes and reducing healthcare costs.

The healthtech market continues to experience robust growth, driven by increasing demand for digital solutions that enhance efficiency and accessibility. Telepatia's focus on AI-powered tools addresses a critical need for innovation in clinical documentation and decision-making, areas often burdened by administrative overhead and potential for human error. The company's success in securing substantial funding from top-tier investors like a16z highlights the significant market opportunity and the perceived strength of its technological solutions.

With this substantial funding, Telepatia is poised to accelerate its product development, expand its engineering and clinical teams, and solidify its market position. The company's strategic expansion into emerging markets could unlock significant value, addressing healthcare disparities and improving the quality of care for millions.